Under Armour, Inc. (UAA)
NYSE: UAA · Real-Time Price · USD
6.73
+0.02 (0.30%)
At close: Aug 6, 2025, 4:00 PM
6.74
+0.01 (0.15%)
After-hours: Aug 6, 2025, 7:08 PM EDT
Regulus Therapeutics Stock Forecast
Stock Price Forecast
The 15 analysts that cover Regulus Therapeutics stock have a consensus rating of "Hold" and an average price target of $7.47, which forecasts a 11.00% increase in the stock price over the next year. The lowest target is $4.00 and the highest is $11.
Price Target: $7.47 (+11.00%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Regulus Therapeutics stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Mar '25 | Apr '25 | May '25 | Jun '25 | Jul '25 | Aug '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 2 | 2 | 2 | 2 | 2 | 2 |
| Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Hold | 16 | 14 | 14 | 14 | 13 | 13 |
| Sell | 3 | 3 | 3 | 3 | 3 | 2 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 20 | 20 | 20 | 19 | 18 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Telsey Advisory Group | Telsey Advisory Group | Hold Maintains $7 | Hold | Maintains | $7 | +4.01% | Aug 4, 2025 |
| Goldman Sachs | Goldman Sachs | Hold Initiates $7 | Hold | Initiates | $7 | +4.01% | Jul 2, 2025 |
| BMO Capital | BMO Capital | Buy Maintains $12 → $9 | Buy | Maintains | $12 → $9 | +33.73% | May 14, 2025 |
| Truist Securities | Truist Securities | Hold Maintains $9 → $7 | Hold | Maintains | $9 → $7 | +4.01% | May 14, 2025 |
| Evercore ISI Group | Evercore ISI Group | Sell Maintains $7 → $6 | Sell | Maintains | $7 → $6 | -10.85% | May 14, 2025 |
Financial Forecast
Revenue This Year
5.12B
from 5.16B
Decreased by -0.88%
Revenue Next Year
5.27B
from 5.12B
Increased by 2.91%
EPS This Year
0.32
from -0.47
EPS Next Year
0.41
from 0.32
Increased by 27.39%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 5.5B | 5.9B | 6.4B | ||
| Avg | 5.1B | 5.3B | 5.5B | ||
| Low | 4.8B | 4.9B | 5.0B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 6.7% | 15.2% | 20.6% | ||
| Avg | -0.9% | 2.9% | 3.5% | ||
| Low | -6.4% | -4.2% | -4.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.47 | 0.63 | 0.78 | ||
| Avg | 0.32 | 0.41 | 0.51 | ||
| Low | 0.17 | 0.24 | 0.32 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | - | 94.1% | 87.9% | ||
| Avg | - | 27.4% | 23.1% | ||
| Low | - | -26.6% | -21.8% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.